国际妇产科学杂志2024，Vol.51Issue(2)：206-209,214,5.DOI:10.12280/gjfckx.20240102
PARP抑制剂与免疫检查点抑制剂联合治疗在妇科恶性肿瘤中的应用
PARP Inhibitors Combined with Immune Checkpoint Inhibitors in the Treatment of Gynecological Malignant Tumors
摘要
Abstract
In recent years the progress of targeted therapy and immunotherapy has developed rapidly,such as poly(ADP-ribose)polymerase inhibitor(PARPi)and immune checkpoint inhibitors(ICI)have changed the traditional treatment pattern of gynecologic tumors,but some patients have limited efficacy or develop drug resistance.Preclinical studies have found that PARPi damages DNA repair process,results in increasing tumor mutation burden and tumor-specific antigen neoantigens,modulates the tumor microenvironment,and stimulates the production of tumor infiltrating lymphocytes(TIL)and promotes anti-tumor immune response,which providing a theoretical basis for the combination treatment of PARPi and ICI.Recently,many clinical studies have found that the combination of PARPi and ICI can significantly improve the prognosis of patients with gynecological malignant tumors.关键词
生殖器肿瘤,女(雌)性/卵巢肿瘤/子宫内膜肿瘤/多(ADP核糖)聚合酶抑制剂/免疫检查点抑制剂/治疗Key words
Genital neoplasms,female/Ovarian neoplasms/Endometrial neoplasms/Poly(ADP-ribose)polymerase inhibitors/Immune checkpoint inhibitors/Therapy引用本文复制引用
周琳,袁琳,万一聪,张林,程文俊,姜旖..PARP抑制剂与免疫检查点抑制剂联合治疗在妇科恶性肿瘤中的应用[J].国际妇产科学杂志,2024,51(2):206-209,214,5.基金项目
国家自然科学基金(82373387,82103286) （82373387,82103286）
江苏省卫健委老年健康研究项目(LKM2022032) （LKM2022032）
